TABLE 3.
Population pharmacokinetics parameter estimates with relative standard errors
| Parameter | Estimate | RSE (%) |
|---|---|---|
| Absorption population parameters | ||
| Fi.d.(Relative bioavailability to s.c. administration) | 1.29 | 6.46 |
| Intradermal administration | ||
| ka‐1 (/d) | 3.54 | 10.1 |
| ka‐2 (/d) | 0.96 | 9.90 |
| MTIME (d) | 0.078 | 9.32 |
| Subcutaneous administration | ||
| ka (/d) | 0.514 | 9.64 |
| Fs.c.Ratiodepot‐1 | 0.322 | 36.6 |
| Lag time (d) | 0.075 | 36.7 |
| Structural model parameters | ||
| Volume of distribution central (L) | 11.5 | 8.02 |
| CL (L/d) | 0.36 | 4.31 |
| Covariate relationships | ||
| CL‐age exponent a | −0.70 | 24.3 |
| CL‐weight exponent b | 0.68 | 36.7 |
| TITRE‐slope | 0.064 | 25.1 |
| Interindividual variability | ||
| ω2 volume of distribution central | 0.069 (shrinkage 0.56%) | 31.2 |
| ω2 TITRE‐slope | 0.537 (shrinkage 28.3%) | 37.1 |
| Residual variability | ||
| σ2 proportional residual error | 0.054 | 13.9 |
| Condition number | 143.70 | |
CL: clearance; F: relative bioavailability; ka: absorption rate constant; MTIME, model event time; RSE: relative standard error.
a
centred around 23 years.
b
centred around 70 kg.